Pfizer Selects Final Two Targets in Hepatic Disease Partnership with Wave Life Sciences

Pfizer has selected the final two targets in a two-year-old, up-to-$911 million collaboration with Wave Life Sciences to develop new treatments for metabolic hepatic diseases, including nonalcoholic steatohepatitis (NASH), Wave said today.